EGF816, INC280, EGF816, GEFITINIB, INC280, EGF816
CINC280A2X02B
Phase 2 small_molecule active
Quick answer
EGF816, INC280, EGF816, GEFITINIB, INC280, EGF816 for cMET-dependent malignancies is a Phase 2 program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Ophthalmics Europe
- Indication
- cMET-dependent malignancies
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active